• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Avita Medical Inc.

    8/9/24 10:40:53 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care
    Get the next $RCEL alert in real time by email
    S-8 1 rcel-20240808.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on August 8, 2024

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8 REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    AVITA MEDICAL, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    85-1021707

    (State or other jurisdiction of

     incorporation or organization)

    I.R.S. Employer

    Identification No.

     

    28159 Avenue Stanford, Suite 220

    Valencia, CA 91355

    (661) 367-9170

    (Address of Principal Executive Offices)

     

    Individual Stock Option Award Agreements

    (Full Title of the Plans)

     

    Nicole Kelsey

    28159 Avenue Stanford, Suite 220

    Valencia, CA 91355

    (661) 367-9170

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

     

    Copy to:

    Christopher H. Cunningham

    Coleman Wombwell

    K&L Gates LLP

    925 Fourth Avenue, Suite 2900

    Seattle, Washington 98104

    (206) 623-7580

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed to register (i) an aggregate of 428,858 shares of common stock that are issuable upon the exercise of stock options and the vesting of restricted stock units ("RSUs") granted pursuant to individual stock option award and RSU award agreements approved by the Registrant’s stockholders at the Registrant’s 2024 Annual Meetings of Stockholders.

     


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act. These documents and the documents incorporated by reference into this registration statement pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    In this registration statement, AVITA Medical, Inc. is sometimes referred to as “Registrant,” “we,” “us,” “our,” or “AVITA”.

     

    Item 3. Incorporation of Documents by Reference.

    The Securities and Exchange Commission (the “Commission”) allows us to “incorporate by reference” the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this registration statement, and later information filed with the SEC will update and supersede this information.

     

    We hereby incorporate by reference into this registration statement the following documents previously filed with the SEC:

    (a)
    Our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 as filed with the Commission on February 22, 2024;
    (b)
    Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 as filed with the Commission on May 13, 2024;
    (c)
    Our Current Reports on Form 8-K dated January 10, 2023, May 30, 2024, June 6, 2024, July 1, 2024 and July 31, 2024;
    (d)
    The description of the Registrant’s common stock set forth on the Form 8-K12B filed June 30, 2020, including any Amendment or reports filed for the purpose of updating this description.

     

    In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing such documents, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement contained herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in any subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    We are a Delaware corporation and certain provisions of Delaware law and our bylaws provide for indemnification of our officers and directors against liabilities that they may incur in such capacities. A summary of the circumstances in which indemnification is provided is discussed below, but this description is qualified in its entirety by reference to our bylaws and to the statutory provisions.

     

    Section 145 of the Delaware General Corporation Law (“DGCL”) provides for, under certain circumstances, the indemnification of our officers, directors, employees and agents against liabilities that they may incur in such capacities. A summary of the circumstances in which such indemnification provided for is contained herein, but that description is qualified in its entirety by reference to the relevant Section of the DGCL.

     

    In general, the statute provides that any director, officer, employee or agent of a corporation may be indemnified against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement, actually and reasonably incurred in a proceeding (including any civil, criminal, administrative or investigative proceeding) to which the individual was a party by reason of such status. Such indemnity may be provided if the indemnified person’s actions resulting in the liabilities: (i) were taken in good faith; (ii) were reasonably believed to have been in or not opposed to our best interest; and (iii) with respect to any criminal action, such person had no reasonable cause to believe the actions were unlawful. Unless ordered by a court, indemnification generally may be awarded only after a determination of independent members of the Board of Directors or a committee thereof, by independent legal counsel or by vote of the stockholders that the applicable standard of conduct was met by the individual to be indemnified. The statutory provisions further provide that to the extent a director, officer, employee or agent is wholly successful on the merits or otherwise in defense of any proceeding to which he was a party, he is entitled to receive indemnification against


    expenses, including attorneys’ fees, actually and reasonably incurred in connection with the proceeding.

     

    Indemnification in connection with a proceeding by or in the right of the Company in which the director, officer, employee or agent is successful is permitted only with respect to expenses, including attorneys’ fees actually and reasonably incurred in connection with the defense. In such actions, the person to be indemnified must have acted in good faith, in a manner believed to have been in our best interest and must not have been adjudged liable to us unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability, in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expense which the Court of Chancery or such other court shall deem proper. Indemnification is otherwise prohibited in connection with a proceeding brought on behalf of the Company in which a director is adjudged liable to us, or in connection with any proceeding charging improper personal benefit to the director in which the director is adjudged liable for receipt of an improper personal benefit.

     

    Delaware law authorizes us to reimburse or pay reasonable expenses incurred by a director, officer, employee or agent in connection with a proceeding in advance of a final disposition of the matter. Such advances of expenses are permitted if the person furnishes to us a written agreement to repay such advances if it is determined that he is not entitled to be indemnified by us.

     

    The statutory section cited above further specifies that any provisions for indemnification of or advances for expenses does not exclude other rights under our certificate of incorporation, corporate bylaws, resolutions of our stockholders or disinterested directors, or otherwise. These indemnification provisions continue for a person who has ceased to be a director, officer, employee or agent of the corporation and inure to the benefit of the heirs, executors and administrators of such persons.

     

    The statutory provision cited above also grants the power to the Company to purchase and maintain insurance policies that protect any director, officer, employee or agent against any liability asserted against or incurred by him in such capacity arising out of his status as such. Such policies may provide for indemnification whether or not the corporation would otherwise have the power to provide for it.

     

    Articles V and VI of our certificate of incorporation provide that we shall indemnify our directors and officers to the fullest extent permitted by the DGCL.

     

    We have purchased directors’ and officers’ liability insurance in order to limit the exposure to liability for indemnification of directors and officers, including liabilities under the Securities Act of 1933.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted for our directors, officers, employees, or agents pursuant to the foregoing provisions or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and, therefore, may be unenforceable.

     

    Item 7. Exemption from Registration Claimed.

    Not applicable.

     

    Item 8. Exhibits.

     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

    4.1

     

    Form of Stock Option Grant (incorporated by reference to Exhibit 10.19 to the registrant's Form 10-K filed on February 23, 2023)†

     

     

     

    4.2

     

    Form of RSU Agreement (incorporated by reference to Exhibit 10.20 to the registrant's Form 10-K filed on February 23, 2023)†

     

     

     

    5.1

     

    Opinion of K&L Gates LLP*

     

     

     

    23.1

     

    Consent of Grant Thornton LLP*

     

     

     

    23.2

     

    Consent of K&L Gates LLP (included in Exhibit 5.1)*

     

     

     

    24.1

     

    Power of Attorney (see Signature Page)

     

     

     

    107

     

    Filing Fee Table*

    † Compensation arrangement

    * Filed herewith.

     

    Item 9. Undertakings.

    (a)
    The undersigned Registrant hereby undertakes:

    (1)
    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement,
    (i)
    to include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii)
    to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
    (iii)
    to include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if this registration statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

    (2)
    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)
    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b)
    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement, relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c)
    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, employees or agents of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and, therefore, may be unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, employee or agent of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Valencia, California, on August 8, 2024.

     

    AVITA MEDICAL, INC.

    By: /s/ James Corbett

    James Corbett

    Chief Executive Officer and Director

     

    Power of Attorney

     

    Each person whose signature appears below hereby constitutes and appoints James Corbett and Nicole Kelsey, and each of them severally, to serve as his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead in any and all capacities the Registration Statement and any and all amendments thereto (including post-effective amendments) and any documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto each of said attorneys full power to act with or without the other, and full power and authority to do and perform, in his or her name and on his or her behalf, every act whatsoever which such attorneys, or any one of them, may deem necessary or desirable to be done in connection therewith as fully and to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities indicated on August 8, 2024.

     

     

    /s/ James Corbett

    Chief Executive Officer and Director

    James Corbett

    (Principal Executive Officer)

     

     

    /s/ David O'Toole

    Chief Financial Officer

    David O'Toole

    (Principal Financial and Accounting Officer)

     

     

    /s/ Lou Panaccio

    Director

    Lou Panaccio

     

     

     

    /s/ Jeremy Curnock Cook

    Director

    Jeremy Curnock Cook

     

     

     

    /s/ Suzanne Crowe

    Director

    Suzanne Crowe

     

     

     

    /s/ Jan Reed Stern

    Director

    Jan Reed Stern

     

     

     

    /s/ Robert McNamara

    Director

    Robert McNamara

     

     

     

    /s/ Cary Vance

    Director

    Cary Vance

     

     


    Get the next $RCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RCEL

    DatePrice TargetRatingAnalyst
    11/20/2025Sell → Neutral
    BTIG Research
    8/8/2025$3.00Neutral → Sell
    BTIG Research
    12/24/2024$25.00Buy
    D. Boral Capital
    4/11/2024Buy → Neutral
    BTIG Research
    6/27/2023$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AVITA Medical to Host Investor Webinar Briefing

    VALENCIA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O'Toole, Chief Financial Officer, on February 18, 2026, at 2:00 p.m. Pacific Standard Time (February 19, 2026, at 9:00 a.m. Australian Eastern Daylight Time). The webinar presentation will cover financial and business results from AVITA Medical's recent fourth-quarter and full-year 2025 earnings webcast and will conclude with a Q&A session. Participan

    2/13/26 9:15:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business Updates Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimbursement headwinds throughout 2025.Gross profit margin of 81.2%, reflecting product mix and inventory-related adjustments.Net use of cash improved for the second consecutive quarter t

    2/12/26 4:01:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies

    First surgeon-reported case using RECELL®, PermeaDerm®, and Cohealyx™ together in a single care pathwayNew clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness for closureRECELL analyses show consistent trends in healing, reduced complications, and shorter hospital stays across studies and real-world registry data VALENCIA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced data from 19 scientific abstracts, including 14 podium presentations, at the 2026 Boswick Burn & Wound Symposium. The presentations

    1/25/26 5:30:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avita Medical upgraded by BTIG Research

    BTIG Research upgraded Avita Medical from Sell to Neutral

    11/20/25 7:57:06 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical downgraded by BTIG Research with a new price target

    BTIG Research downgraded Avita Medical from Neutral to Sell and set a new price target of $3.00

    8/8/25 8:17:21 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on Avita Medical with a new price target

    D. Boral Capital initiated coverage of Avita Medical with a rating of Buy and set a new price target of $25.00

    12/24/24 7:10:27 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    SEC Filings

    View All

    SEC Form 10-K filed by Avita Medical Inc.

    10-K - AVITA Medical, Inc. (0001762303) (Filer)

    2/12/26 5:20:54 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AVITA Medical, Inc. (0001762303) (Filer)

    2/12/26 4:15:26 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avita Medical Inc.

    SCHEDULE 13G/A - AVITA Medical, Inc. (0001762303) (Subject)

    1/30/26 1:27:06 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcnamara Robert bought $45,000 worth of shares (10,000 units at $4.50), increasing direct ownership by 13% to 86,771 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/29/25 4:30:09 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    CFO O'Toole David D bought $9,040 worth of shares (2,000 units at $4.52), increasing direct ownership by 7% to 31,657 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/26/25 4:30:23 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Director Mcnamara Robert bought $50,000 worth of shares (10,000 units at $5.00), increasing direct ownership by 15% to 76,771 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/20/25 6:11:04 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcnamara Robert bought $45,000 worth of shares (10,000 units at $4.50), increasing direct ownership by 13% to 86,771 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/29/25 4:30:09 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    CFO O'Toole David D bought $9,040 worth of shares (2,000 units at $4.52), increasing direct ownership by 7% to 31,657 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/26/25 4:30:23 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Director Mcnamara Robert bought $50,000 worth of shares (10,000 units at $5.00), increasing direct ownership by 15% to 76,771 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/20/25 6:11:04 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Leadership Updates

    Live Leadership Updates

    View All

    AVITA Medical Announces Changes to its Board of Directors

    Veteran healthcare executive Joe Woody joins the BoardLou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025. "We are pleased to welcome Joe to the Board. His extensive track record leading global med-tech companies and driving commercial excellence will be invaluable as we continue to scale AVITA Medical's growth," said Cary Vance, Interim CEO of

    1/5/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Announces CEO Transition

    Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)) ("AVITA Medical", or the "Company"), a leading therapeutic acute wound care company, today announced that the Board of Directors has named Chairman of the Board Cary Vance as Interim Chief Executive Officer, effective immediately. In conjunction with this appointment, Jim Corbett is leaving his positions as CEO and member of the Board. Mr. Vance will continue to serve as Chairman of the Board, while Board m

    10/16/25 6:15:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance

    Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic.The Board thanks Lou Panaccio, its long-standing Board Chair, for his service as he steps down and Cary Vance assumes the Chair position. VALENCIA, Calif. and MELBOURNE, Australia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, announced today the appointment to its Board of Directors (the "Board") of Michael Tarnoff, MD, FACS, as a non-executive Director, effective August 6, 2025. Dr. Tarnoff's appointment comes as the Company fu

    8/6/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Financials

    Live finance-specific insights

    View All

    AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business Updates Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimbursement headwinds throughout 2025.Gross profit margin of 81.2%, reflecting product mix and inventory-related adjustments.Net use of cash improved for the second consecutive quarter t

    2/12/26 4:01:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook

    VALENCIA, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal year 2025. The Company also provided its preliminary outlook for fiscal year 2026, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. Pacific Time (Thursday, January 15, 2026, at 12:15 p.m. Australian Eastern Daylight Time). The webcast can be accessed through AVITA Medical's website at: https://ir.avitamedical.com/events-and-presentations

    1/13/26 8:25:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA® Medical Reports Third Quarter 2025 Financial Results

    VALENCIA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the third quarter ended September 30, 2025. Financial Results Commercial revenue of $17.1 million, representing a 13% decrease compared to the same period in 2024.Cash, cash equivalents, and marketable securities totaled $23.3 million as of Sept. 30, 2025.Operating expenses decreased by 24%, or $7.2 million, to $23.0 million, compared with $30.2 million in the corresponding period last year, as the Company continues to streamline operat

    11/6/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avita Medical Inc.

    SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

    2/13/24 4:58:57 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Avita Medical Inc.

    SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

    1/26/24 4:23:41 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

    SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)

    2/9/23 11:07:47 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care